Dr. Mitra is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1545 Divisadero St
San Francisco, CA 94143Phone+1 415-353-7900Fax+1 415-353-2640
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 2011 - 2014
University of California (San Francisco)Residency, Internal Medicine, 2009 - 2011- University of California San Francisco School of MedicineClass of 2009
Certifications & Licensure
CA State Medical License 2011 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- FPT155 in Patients With Advanced Solid Tumors Start of enrollment: 2018 Nov 14
Publications & Presentations
PubMed
- 1130 citationsThe CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumorsStephen B. Willingham, Jens Peter Volkmer, Andrew J. Gentles, Debashis Sahoo, Piero Dalerba
Proceedings of the National Academy of Sciences of the United States of America. 2012-04-24 - 97 citationsUsp16 contributes to somatic stem-cell defects in Down’s syndromeMaddalena Adorno, Shaheen S. Sikandar, Siddhartha Mitra, Angera H. Kuo, Benedetta Nicolis di Robilant
Nature. 2013-09-19 - 480 citationsNeuronal Activity Promotes Glioma Growth through Neuroligin-3 Secretion.Humsa S. Venkatesh, Tessa Johung, Viola Caretti, Alyssa Noll, Yujie Tang
Cell. 2015-05-07
Journal Articles
- BMI1 Is a Therapeutic Target in Recurrent MedulloblastomaSiddhartha Mitra, MD, Nature
Press Mentions
Drug Combination for Children with MYC Amplified MedulloblastomaJanuary 16th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
